GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Short Interest

iX Biopharma (SGX:42C) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of iX Biopharma's Short Interest

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iX Biopharma's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Short Interest distribution charts can be found below:

* The bar in red indicates where iX Biopharma's Short Interest falls into.


;
;

iX Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Short Interest
Comparable Companies
SGX:BFK ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA SHSE:688506 TSE:4507 BOM:500087 SZSE:000538 NSE:TORNTPHARM UTHR BOM:500124 NBIX BOM:532321
Traded in Other Exchanges
N/A
Address
1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
Website
https://www.ixbiopharma.com
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines